All In Biotech

Drug Trial Radar · NCT07613710

A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Jun 13, 2025

Primary completion

Feb 9, 2027

Study completion Feb 16, 2027

Sponsor

Lead sponsor
H. Lundbeck A/SIndustry
Sponsor type
Industry
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the trial is to determine if Lu AH69593 is safe and well tolerated. The trial will also look at how the body processes Lu AH69593 with and without food.

Conditions

  • Narcolepsy

Interventions

  • Lu AH69593Drug

    Lu AH69593 will be administered per schedule specified in the arm description.

  • PlaceboDrug

    Placebo will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Day 90
  2. Bond Lader Visual Analogue Scale (VAS) dimension scores (Alertness, Contentedness, and Calmness)Time frame: Baseline up to Day 84
  3. Psychomotor Vigilance Task (PVT) Parameter - Change From Baseline in Reaction Time to StimuliTime frame: Baseline, up to Day 11
  4. PVT Parameter - Change From Baseline in Number of Errors of OmissionTime frame: Baseline, up to Day 11
  5. PVT Parameter - Change From Baseline in Number of Errors of Commission (Response Without Stimulus)Time frame: Baseline, up to Day 11
  6. Number of Participants With Suicidal Ideation and Behaviour Based on the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline up to Day 90
  7. Area Under the Curve (AUC) From Zero to Time of Last Quantifiable Concentration (AUC0-t) of Lu AH69593Time frame: Up to 84 days
  8. Maximum Observed Plasma Concentration (Cmax) of Lu AH69593Time frame: Up to 84 days
  9. Time to Reach Cmax (Tmax) of Lu AH69593Time frame: Up to 84 days
  10. AUC From Time Zero to Infinity (AUC0-inf)Time frame: Up to 6 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Terveystalo Helsinki, Sleep Clinic

    Helsinki, Finland · Recruiting

  • CRST, Clinical Research Services Turku

    Turku, Finland · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.